Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Pre-Market Stock Futures: Futures are trading lower as we prepare to finally end what has been one of the most volatile weeks in recent memory, with oil hitting its highest level since 2024. After a s
Focus Partners Advisor Solutions LLC Acquires Shares of 2,909 Regeneron Pharmaceuticals, Inc. $REGN
04:00am, Friday, 06'th Mar 2026
Focus Partners Advisor Solutions LLC bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) in the undefined quarter, according to its most recent disclosure with the Securitie
2 Biotech Giants to Buy in 2026
08:15am, Thursday, 05'th Mar 2026
Both of these players are leaders in their fields.
Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
12:22pm, Wednesday, 04'th Mar 2026
Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Elo Mutual Pension Insurance Co Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN
04:29am, Tuesday, 03'rd Mar 2026
Elo Mutual Pension Insurance Co increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 23.0% during the third quarter, according to its most recent Form 13F filing with
REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria
10:10am, Monday, 02'nd Mar 2026
Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.
Compound Planning Inc. Invests $557,000 in Regeneron Pharmaceuticals, Inc. $REGN
03:51am, Sunday, 01'st Mar 2026
Compound Planning Inc. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 990
10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)
08:10am, Saturday, 28'th Feb 2026
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversifica
Why Dupixent Keeps Regeneron A Top Big Pharma Pick
08:00am, Friday, 27'th Feb 2026
Regeneron Pharmaceuticals ended 2025 and started this year on a high note. Regeneron and its partner Sanofi are among the leaders in the immune-mediated inflammatory diseases market. In Q4, Dupixent s
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment
Fox Run Management L.L.C. Acquires Shares of 4,413 Regeneron Pharmaceuticals, Inc. $REGN
04:52am, Wednesday, 25'th Feb 2026
Fox Run Management L.L.C. bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securit
2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years
07:16pm, Tuesday, 24'th Feb 2026
Regeneron's main growth driver should perform well through the end of the decade. The biotech should launch newer medicines in the coming years.
Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition
01:47pm, Tuesday, 24'th Feb 2026
• Regeneron Pharmaceuticals stock is facing resistance. Why are REGN shares declining?
Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Approbation chez les adultes et les enfants âgés de 6
